SRPT Aug 2024 165.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:48PM EDT. Market open.
Loading interactive chart…
- Investor's Business Daily
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Sarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy failed in final-phase testing.
- Barrons.com
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
The drug company said a gene therapy it is testing failed to improve motor function in boys aged 4 to 7.
- Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 31, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 31, 2024 (the "Grant Date") that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 9 individuals hired by Sarepta in May 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(
© 2024 Yahoo. All rights reserved.